SpringWorks Therapeutics Analysis
| SWTXDelisted Stock | USD 46.99 0.00 0.00% |
SpringWorks Therapeutics holds a debt-to-equity ratio of 0.017. With a high degree of financial leverage come high-interest payments, which usually reduce SpringWorks Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
SpringWorks Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. SpringWorks Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps SpringWorks Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect SpringWorks Therapeutics' stakeholders.
For most companies, including SpringWorks Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for SpringWorks Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, SpringWorks Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that SpringWorks Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which SpringWorks Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of SpringWorks Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, SpringWorks Therapeutics is said to be less leveraged. If creditors hold a majority of SpringWorks Therapeutics' assets, the Company is said to be highly leveraged.
SpringWorks Therapeutics is overvalued with Real Value of 37.27 and Hype Value of 46.99. The main objective of SpringWorks Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what SpringWorks Therapeutics is worth, separate from its market price. There are two main types of SpringWorks Therapeutics' stock analysis: fundamental analysis and technical analysis.
The SpringWorks Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. SpringWorks Therapeutics is usually not traded on Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday. SpringWorks Stock trading window is adjusted to America/New York timezone.
SpringWorks |
SpringWorks Stock Analysis Notes
About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.41. SpringWorks Therapeutics had not issued any dividends in recent years. SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. To find out more about SpringWorks Therapeutics contact Saqib JD at 203 883 9490 or learn more at https://www.springworkstx.com.SpringWorks Therapeutics Investment Alerts
| SpringWorks Therapeutics is not yet fully synchronised with the market data | |
| SpringWorks Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 191.59 M. Net Loss for the year was (258.13 M) with profit before overhead, payroll, taxes, and interest of 204.8 M. | |
| SpringWorks Therapeutics currently holds about 334.54 M in cash with (175.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81. | |
| Over 87.0% of the company shares are owned by institutional investors |
SpringWorks Therapeutics Upcoming and Recent Events
Earnings reports are used by SpringWorks Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
SpringWorks Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.54 B.SpringWorks Profitablity
The company has Profit Margin (PM) of (1.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.64.SpringWorks Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SpringWorks Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SpringWorks Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SpringWorks Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
SpringWorks Therapeutics Outstanding Bonds
SpringWorks Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. SpringWorks Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most SpringWorks bonds can be classified according to their maturity, which is the date when SpringWorks Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
| SPR 9375 30 NOV 29 Corp BondUS85205TAN00 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
| SPRINT NEXTEL P Corp BondUS85208NAE04 | View | |
| Sprint 6875 percent Corp BondUS852060AD48 | View | |
| Sprint 875 percent Corp BondUS852060AT99 | View |
SpringWorks Therapeutics Predictive Daily Indicators
SpringWorks Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of SpringWorks Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 6.0E-4 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 47.0 | |||
| Day Typical Price | 46.99 | |||
| Market Facilitation Index | 0.03 | |||
| Price Action Indicator | (0.01) |
SpringWorks Therapeutics Debt to Cash Allocation
As SpringWorks Therapeutics follows its natural business cycle, the capital allocation decisions will not magically go away. SpringWorks Therapeutics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
SpringWorks Therapeutics currently holds 7.91 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. SpringWorks Therapeutics has a current ratio of 9.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about SpringWorks Therapeutics' use of debt, we should always consider it together with its cash and equity.SpringWorks Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the SpringWorks Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of SpringWorks Therapeutics, which in turn will lower the firm's financial flexibility.SpringWorks Therapeutics Corporate Bonds Issued
About SpringWorks Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how SpringWorks Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling SpringWorks shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as SpringWorks Therapeutics. By using and applying SpringWorks Stock analysis, traders can create a robust methodology for identifying SpringWorks entry and exit points for their positions.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding SpringWorks Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in SpringWorks Stock
If you are still planning to invest in SpringWorks Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SpringWorks Therapeutics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |